BANK VONTOBEL/CALL/VERTEX PHARMACEUTICALS/400/0.1/21.06.24 | Delayed Deutsche Boerse AG 18:40:24 04/06/2024 BST | ||
| 6.69 EUR | +6.02% |
|
| Current month | +29.04% | ||
| 1 month | +266.86% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 04/06/24 | 6.69 | +6.02% |
| 03/06/24 | 6.31 | +29.04% |
| 31/05/24 | 4.89 | +23.48% |
| 30/05/24 | 3.96 | -7.26% |
| 29/05/24 | 4.27 | -7.17% |
Delayed Quote Deutsche Boerse AG
Last update June 04, 2024 at 06:40 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VM3RNF |
| ISIN | DE000VM3RNF8 |
| Date issued | 09/10/2023 |
| Strike | 400 $ |
| Maturity | 21/06/2024 (17 Days) |
| Parity | 10 : 1 |
| Emission price | 2.1 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.69 € |
|---|---|
| Lowest since issue | 1.29 € |
| Spread | 0.04 € |
| Spread % | 0.56% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
470.2
USD
Average target price
463.5
USD
Spread / Average Target
-1.41%
- Stock Market
- Warrants
- Warrant
